



RCE/1631  
#20  
RP  
107-22

**REQUEST  
FOR  
CONTINUED EXAMINATION (RCE)  
TRANSMITTAL**

Address to:  
Commissioner for Patents  
Box RCE  
Washington, DC 20231

Application Number	09/314,540
Filing Date	May 19, 1999
First Named Inventor	Langer, et al
Art Unit	1631
Examiner Name	Martinell, J.
Attorney Docket Number	0492611-0335

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

RECEIVED

OCT 03 2002

TECH CENTER 1600/2900

1. **Submission required under 37 CFR 1.114**

- a. ☐ Previously submitted
- i. ☐ Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on \_\_\_\_\_  
(Any unentered amendment(s) referred to above will be entered).
- ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_
- iii. ☐ Other \_\_\_\_\_
- b. ☒ Enclosed
- i. ☒ Amendment/Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)
- iv. ☒ Other Extension of time

2. **Miscellaneous**

- a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)
- b. ☐ Other \_\_\_\_\_

3. **Fees**

The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

- a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 03-1721
- i. ☒ RCE fee required under 37 CFR 1.17(e) **10/01/2002 CHNGUYEN 00000033 09314540**
- ii. ☒ Extension of time fee (37 CFR 1.136 and 1.17) **01 FC:279 370.00 OP**
- iii. ☐ Other \_\_\_\_\_
- b. ☒ Check in the amount of \$ 370.00 enclosed and \$460.00 for the extension fee.
- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

Name (Print/Type)	Valarie B. Rosen	Registration No. (Attorney/Agent)	45,698
Signature	<i>Valarie Rosen</i>	Date	September 25, 2002

**CERTIFICATE OF MAILING OR TRANSMISSION**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name (Print/Type)	Susan M. Dinsmore	Date	September 25, 2002
Signature	<i>Susan M. Dinsmore</i>		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, DC 20231.

RECEIVED

OCT 03 2002

TECH CENTER 1600/2900

Attorney Docket No.: 0492611-0335 (MIT 8070)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Langer, *et al*

Examiner: Martinell, J.

Serial No.: 09/314,540

Art Unit: 1631

Filing Date: May 19, 1999

Title: MODIFICATION OF SURFACES USING BIOLOGICAL  
RECOGNITION EVENTS

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**RESPONSE TO ADVISORY ACTION UNDER 37 C.F.R. §1.116**

This **Response to Advisory Action** is filed in response to the Advisory Action mailed June 21, 2002, objecting to claims 11 and 12 and rejecting 1-3, 6-10, 13, 65-68, 73, and 74. The sole cited reference is Hoffman (*Artificial Organs*, 16: 43-49, 1992). The following amendments and remarks remove all grounds for rejection of the application, thereby placing it in condition for allowance.

**Amendment**

Please amend the claims as follows:

1. (Thrice amended) A composition comprising a biodegradable polymer having a ligand attached thereto, wherein said ligand is attached to said biodegradable polymer via an anchor-adapter-tag unit comprising an anchor attached to or incorporated into the polymer and through which the unit is retained on the polymer, a tag attached to the ligand, and an adapter that links the anchor and the tag.

2. (Thrice amended) A composition comprising a biomaterial architecture having a ligand attached thereto through a biomolecular interaction, wherein said biomaterial architecture comprises a polymer having an anchor moiety incorporated therein or attached thereto, and wherein said biomolecular interaction is effected by an anchor-adapter-tag unit comprising the

DI  
cont

anchor, a tag attached to the ligand, and an adapter that links the anchor and the tag, wherein the unit is retained on the polymer by the anchor.

---

The amendments to claims 1 and 2 are made to more particularly point out and distinctly claim the subject matter of the invention. The amendments are supported by material throughout the specification as filed. No new matter is entered by any of these amendments. A marked-up version of the amendments to the specification and claims is included in the attachment captioned "Version with Markings to Show Changes Made for USSN 09/314,540".